Onyx/Bayer Expect 2008 Launch For Nexavar In Liver Cancer

Companies will submit sNDA as soon as possible following study halt because of “superior overall survival efficacy.”

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet